Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
tags : Trial crawled date : 2022 - 10 - 20 save search
Summit Therapeutics Presents Ri-CoDIFy Trial Results for Microbiome-Sparing Ridinilazole at IDWeek 2022
Published: 2022-10-20 (Crawled : 22:00) - globenewswire.com
SMMT | $3.49 -0.29% -0.29% 1.2M
|
Health Technology
|
| O: 0.83%
H: 0.0%
C: -7.44%
trial therapeutics
Talaris Cleared to Continue Kidney Transplant Trial after Patient Death
Published: 2022-10-20 (Crawled : 16:00) - biospace.com/
SNY | News | $47.125 1.78% 1.75% 2.1M
|
Health Technology
|
| O: -1.19%
H: 0.0%
C: 0.0%
cleared kidney trial
Erasca Announces Clinical Trial Collaboration and Supply Agreement with Pfizer to Evaluate ERAS-007 and Palbociclib Combination
Published: 2022-10-20 (Crawled : 14:20) - biospace.com/
ERAS | $1.85 3.35% 3.24% 330K
|
|
| O: 2.12%
H: 1.24%
C: -1.94%
PFE | News A | $26.26 1.0% -0.08% 36M
|
Health Technology
|
| O: 0.37%
H: 0.32%
C: -0.83%
eras-007 collaboration trial agreement
Femasys Inc. Provides Strategic Update on its FemaSeed® Pivotal Trial Design to Expedite Clinical Program Advancement
Published: 2022-10-20 (Crawled : 13:00) - globenewswire.com
FEMY | $1.27 -3.79% -3.94% 220K
|
Manufacturing
|
| O: -1.69%
H: 6.03%
C: 6.03%
femaseed program trial update
gammaCore Non-Invasive Vagus Nerve Stimulation (nVNS) Improves Neurobehavioral Outcomes in a Model of Traumatic Brain Injury Pre-clinical trial
Published: 2022-10-20 (Crawled : 13:00) - biospace.com/
ECOR | $5.94 5.13% 4.88% 6.7K
|
Health Technology
|
| O: -1.41%
H: 4.67%
C: 1.9%
pre-clinical trial train
Iterum Announces First Patient Dosed in REASSURE, a Phase 3 Clinical Trial of Oral Sulopenem in Uncomplicated Urinary Tract Infections
Published: 2022-10-20 (Crawled : 12:00) - biospace.com/
ITRM | $1.59 11.19% 10.06% 200K
|
Health Technology
|
| O: -5.05%
H: 5.32%
C: -0.53%
sulopenem infections trial
First Patient Enrolled in Palatin's Phase 2 study of PL8177 in Ulcerative Colitis Trial
Published: 2022-10-20 (Crawled : 12:00) - prnewswire.com
PTN | $1.72 -6.52% 0.0% 210K
|
Health Technology
|
| O: 1.68%
H: 0.62%
C: -4.55%
pl8177 trial study phase 2 ulcerative colitis
Gainers vs Losers
| 75% | 25% |
Top 10 Gainers
MTTR | News M | $4.78 174.71% 63.6% 72M
|
AGBA | $2.565 105.2% 51.27% 200M
|
Finance
MLEC | $2.44 74.29% 42.62% 78M
|
n/a
EDBL | News | $6.28 67.02% 40.13% 16M
|
ATGL | $2.91 48.81% 32.8% 180K
|
ZAPP | $0.2175 47.16% 32.05% 16M
|
n/a
ONFO | $0.6075 38.38% 27.74% 7.3M
|
n/a
VIVK | $1.48 38.32% 27.7% 530K
|
Professional, Scientific, and T...
MNTS | $0.5 35.69% 26.3% 4.8M
|
SDIG A | $3.635 35.13% 26.0% 1M
|
Your saved searches
Save your searches and get alerts when important news are released.